# Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

> **NCT06362707** · PHASE2 · RECRUITING · sponsor: **Helse Stavanger HF** · enrollment: 200 (estimated)

## Conditions studied

- Cognitive Decline, Mild
- Alzheimer Disease

## Interventions

- **DRUG:** Fasudil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06362707
- **Lead sponsor:** Helse Stavanger HF
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362707, "Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06362707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*